Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer||
||Other / Industry||
||109||All||18 Years and older (Adult, Senior)||NCT00771953||HP-00043076; 0822GCC
|November 2008||May 2012||December 2014||October 15, 2008||May 17, 2017||July 22, 2013||